AIGH Capital and Orin Hirschman disclose 7.9% Biofrontera (BFRI) ownership in Schedule 13G/A
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Biofrontera Inc. received an updated ownership disclosure from AIGH-related entities and Orin Hirschman. The reporting persons state beneficial ownership of 915,210 shares of common stock, representing 7.9% of the class. These securities are held with sole voting and dispositive power.
The filing notes an additional 14,642,510 common shares are issuable upon conversion of preferred shares and convertible notes but are not currently convertible or exercisable because of beneficial ownership limitations on conversion. The securities are described as acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of Biofrontera.
Positive
- None.
Negative
- None.
FAQ
What percentage of Biofrontera Inc. (BFRI) does AIGH and Orin Hirschman report owning?
The reporting group states beneficial ownership of 7.9% of Biofrontera’s common stock. This corresponds to 915,210 shares with sole voting and dispositive power, making them a significant but non-controlling shareholder under Schedule 13G rules.
Who are the reporting persons in the Biofrontera Inc. (BFRI) Schedule 13G/A amendment?
The filing is jointly made by AIGH Capital Management LLC, AIGH Investment Partners LLC, and Orin Hirschman. Hirschman is identified as Managing Member of AIGH Capital Management and president of AIGH Investment Partners, with the entities collectively described as the reporting persons.
Is the AIGH and Orin Hirschman stake in Biofrontera (BFRI) intended to influence control?
The certification states the securities were acquired and are held in the ordinary course of business. It further states they were not acquired and are not held to change or influence control of Biofrontera, consistent with the passive investor framework of Schedule 13G.
What class of Biofrontera (BFRI) securities is covered by this Schedule 13G/A filing?
The filing covers Biofrontera Inc. common stock with a par value of $0.001 per share. The CUSIP number identified is 09077D209, which helps uniquely identify this specific class of securities in the market.